<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20046" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Inhaled Corticosteroids</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Liang</surname>
            <given-names>Tian Z.</given-names>
          </name>
          <aff>SUNY Downstate Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chao</surname>
            <given-names>Jennifer H.</given-names>
          </name>
          <aff>SUNY Downstate</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tian Liang declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jennifer Chao declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20046.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Inhaled corticosteroids (ICS) are the FDA-indicated treatment of choice in preventing asthma exacerbation in patients with persistent asthma. Persistent asthma is classified by symptoms more than two days a week, more than three nighttime awakenings per month, more than twice a week using short-acting beta-2 agonists for symptom control, or any limitation of normal activity due to asthma. Regular use of these medications reduces the frequency of asthma symptoms, bronchial hyper-responsiveness, risk of serious exacerbation, and improves the quality of life. This activity describes the mode of action of inhaled corticosteroids, including mechanism of action, pharmacology, adverse event profiles, eligible patient populations, monitoring, and highlights the role of the interprofessional team in the management of these patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the mechanism of action of inhaled corticosteroids.</p></list-item><list-item><p>Identify the indications for using inhaled corticosteroid therapy.</p></list-item><list-item><p>Review the potential adverse reactions of inhaled corticosteroids.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance inhaled corticosteroid therapy and improve outcomes and minimize adverse events.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20046&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20046">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20046.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Inhaled corticosteroids (ICS) are the FDA-indicated treatment of choice in preventing asthma exacerbations in patients with persistent asthma.<xref ref-type="bibr" rid="article-20046.r1">[1]</xref>&#x000a0; Persistent asthma is classified by symptoms more than two days a week, more than three nighttime awakenings per month, more than twice a week using short-acting beta-2 agonists for symptom control, or any limitation of normal activity due to asthma.<xref ref-type="bibr" rid="article-20046.r1">[1]</xref> Regular use of these medications reduces the frequency of asthma symptoms, bronchial hyperresponsiveness, risk of serious exacerbations and improves the quality of life.<xref ref-type="bibr" rid="article-20046.r2">[2]</xref> These medications are initiated in a stepwise fashion based on the frequency and severity of the asthma symptoms. Low, medium, and high-dose inhaled corticosteroids are available to treat mild, moderate, and severe persistent asthma, respectively.<xref ref-type="bibr" rid="article-20046.r3">[3]</xref> If inhaled corticosteroids alone are not adequate in controlling a patient's asthma symptoms, other controller medications such as long-acting beta-agonists or leukotriene receptor antagonists may also be started. Asthma controller medications often are used in conjunction with short-acting beta-agonists such as albuterol as part of an asthma action plan to address acute and chronic symptoms.<xref ref-type="bibr" rid="article-20046.r1">[1]</xref></p>
        <p>Recently updated guidelines also recommend ICS to be used for acute asthma symptoms in conjunction with beta-2 agonists in adolescents and adults.<xref ref-type="bibr" rid="article-20046.r4">[4]</xref>&#x000a0; Inhaled corticosteroids are also prescribed off-label (non-FDA approved) to manage chronic obstructive pulmonary disease (COPD). Up to 40% to 50% of patients with COPD receive inhaled corticosteroid therapy. Data suggests that these medications decreased the number of exacerbations and may slow the progression of lung disease.<xref ref-type="bibr" rid="article-20046.r5">[5]</xref> There is, however, minimal impact of inhaled corticosteroids on lung function and mortality. Inhaled corticosteroids are most often used in COPD as an adjunct to long-acting inhaled bronchodilators, but the clinician may initiate them earlier if there is an asthmatic component in a given patient's lung disease.<xref ref-type="bibr" rid="article-20046.r6">[6]</xref></p>
      </sec>
      <sec id="article-20046.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Inhaled corticosteroids have potent glucocorticoid activity and work directly at the cellular level by reversing capillary permeability and lysosomal stabilization to reduce inflammation. The onset of action is gradual and may take anywhere from several days to several weeks for maximal benefit with consistent use. Metabolism is through the hepatic route, with a half-life elimination of up to 24 hours.&#x000a0;<xref ref-type="bibr" rid="article-20046.r2">[2]</xref></p>
      </sec>
      <sec id="article-20046.s4" sec-type="Administration">
        <title>Administration</title>
        <p>These drugs are administered through the inhalation route directly to their sites of action.&#x000a0;This mode of administration decreases the dose required for the desired effect as it bypasses the first-pass metabolism in drugs taken orally. The reduced systemic bioavailability also minimizes side effects.<xref ref-type="bibr" rid="article-20046.r7">[7]</xref>&#x000a0; Inhaled corticosteroids come in liquid capsule formulations given through a nebulizer machine, metered-dose inhalers (MDI) administered through spacers, and dry powder inhalers (DPI). The advantages and disadvantages of each are as follows:<xref ref-type="bibr" rid="article-20046.r8">[8]</xref><xref ref-type="bibr" rid="article-20046.r9">[9]</xref></p>
        <p>Nebulizer</p>
        <list list-type="bullet">
          <list-item>
            <p>Advantages: Coordination with the patient not required, high doses possible</p>
          </list-item>
          <list-item>
            <p>Disadvantages: Expensive, more time required (10 to 15 minutes per dose), contamination of the machine</p>
          </list-item>
        </list>
        <p>Metered Dose Inhalers (MDI)</p>
        <list list-type="bullet">
          <list-item>
            <p>Advantages: Less expensive than nebulizers, convenient, faster to use, has a dose counter.</p>
          </list-item>
          <list-item>
            <p>Disadvantages: Coordination is essential if not using a mask, pharyngeal deposition, difficult to deliver high doses</p>
          </list-item>
        </list>
        <p>Dry Powder Inhaler (DPI)</p>
        <list list-type="bullet">
          <list-item>
            <p>Advantages: Portable, dose counter, less coordination needed compared to MDI</p>
          </list-item>
          <list-item>
            <p>Disadvantages: Needs higher inspiratory flow to use effectively, pharyngeal deposition of medication, cannot use in mechanically vented patients</p>
          </list-item>
        </list>
        <p>Drug deposition of inhaled corticosteroids in children older than five is similar to that of adults, so the method of administration of ICS in these age groups should be decided based on patient and family preference. However, toddlers and infants cannot reliably generate a sufficient inspiratory flow rate to use dry powder inhalers, so this method of delivery is not recommended for this age group. The recommendation is that young children either use a nebulizer or MDI with a mask and spacer to deliver inhaled corticosteroids.<xref ref-type="bibr" rid="article-20046.r10">[10]</xref></p>
        <p>Many different brands of inhaled corticosteroids are available on the market with similar efficacy between the formulations. Widely used inhaled corticosteroids include budesonide, fluticasone, beclomethasone, flunisolide, mometasone, and triamcinolone.<xref ref-type="bibr" rid="article-20046.r11">[11]</xref></p>
      </sec>
      <sec id="article-20046.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Local adverse effects of inhaled corticosteroids include dysphonia, oral candidiasis, reflex cough, and bronchospasm. These adverse effects are less common with low-dose inhaled corticosteroids than with high-dose inhaled corticosteroids. These adverse effects are also mitigated by spacer use when taking the medication via metered-dose inhalers.<xref ref-type="bibr" rid="article-20046.r12">[12]</xref></p>
        <p>Up to 50-60% of patients report dysphonia while using inhaled corticosteroids. It is due to myopathy of the laryngeal muscles and mucosal irritation, and it is reversible after withdrawing treatment.<xref ref-type="bibr" rid="article-20046.r13">[13]</xref> Oral candidiasis (thrush) is another common complaint among users of inhaled corticosteroids. This risk increases in elderly patients and patients who also take oral steroids, high dose ICS, or antibiotics. Laryngeal and esophageal candidiasis also has been described in the literature.<xref ref-type="bibr" rid="article-20046.r14">[14]</xref><xref ref-type="bibr" rid="article-20046.r15">[15]</xref> It is advisable to have the patient rinse their mouth out after ICS use to prevent oral candidiasis. Treatments for candidiasis include clotrimazole, miconazole, and nystatin.<xref ref-type="bibr" rid="article-20046.r16">[16]</xref></p>
        <p>Inhaled corticosteroid use has correlations with a reduction in growth velocity in children with asthma. However, these effects in low doses of inhaled corticosteroids are small, nonprogressive, and potentially reversible. Inadequate control of asthma also is associated with reductions in growth velocity, and early intervention with inhaled corticosteroids significantly improves asthma control.<xref ref-type="bibr" rid="article-20046.r7">[7]</xref> Thus, the benefits of ICS use outweighs the risk. Other potential systemic adverse effects of inhaled corticosteroids are rare and/or clinically insignificant, including cataracts, glaucoma, hypothalamic-pituitary-adrenal axis dysfunction, and impaired glucose metabolism.<xref ref-type="bibr" rid="article-20046.r12">[12]</xref> Symptomatic patients on long-term, inhaled corticosteroids should be screened for these conditions, or asymptomatic patients on the long-term, high-dose ICS.<xref ref-type="bibr" rid="article-20046.r7">[7]</xref></p>
        <p>There is conflicting evidence on the effect of inhaled corticosteroids on bone metabolism and osteoporosis. High doses of ICS are associated with an increased risk of fracture. Adult patients on chronic ICS therapy should undergo bone density measurement. Routine testing of bone density in children is not needed, but recommendations include supplementation with adequate vitamin D and calcium.<xref ref-type="bibr" rid="article-20046.r7">[7]</xref></p>
      </sec>
      <sec id="article-20046.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are few absolute contraindications to the various inhaled corticosteroids available in the United States.<xref ref-type="bibr" rid="article-20046.r17">[17]</xref>&#x000a0;These include hypersensitivity to the medication and severe hypersensitivity to milk proteins/lactose. Dry powder inhalers often contain lactose as a stabilizing agent. Though not intentional, there have been reports of milk protein contamination within lactose-containing medications, including dry powdered inhalers.<xref ref-type="bibr" rid="article-20046.r18">[18]</xref> Therefore, in patients with severe milk protein or lactose allergies, DPI asthma medications are contraindicated. Additional contraindications in Canadian labeling include untreated fungal, bacterial, and tubercular infections of the respiratory tract. Inhaled corticosteroids are recommended therapy for treating asthma during pregnancy. Maternal ICS use during pregnancy has <italic toggle="yes">not</italic> demonstrated an increase in the risk of congenital malformations or impaired fetal growth.&#x000a0;<xref ref-type="bibr" rid="article-20046.r19">[19]</xref><xref ref-type="bibr" rid="article-20046.r20">[20]</xref></p>
      </sec>
      <sec id="article-20046.s7" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Many healthcare professionals prescribe inhaled corticosteroids, including the nurse practitioner, primary care provider, pulmonologist, ENT surgeon, allergist, and emergency department physician. It is essential to know the adverse effects of inhaled corticosteroids. Patients should receive education about the local adverse effects and strategies to reduce their impact. More importantly, inhaled corticosteroid use correlates with a reduction in growth velocity in children with asthma. However, these effects in low doses of inhaled corticosteroids are small, nonprogressive, and potentially reversible.<xref ref-type="bibr" rid="article-20046.r12">[12]</xref> Inadequate control of asthma also is associated with reductions in growth velocity, and early intervention with inhaled corticosteroids significantly improves asthma control. Thus, the benefits of ICS use outweighs the risk. To optimize therapeutic benefit and mitigate adverse events, an interprofessional healthcare team that includes clinicians, mid-level practitioners, nurses, and pharmacists&#x000a0;should oversee and manage patients on inhaled corticosteroids. This approach will lead to the best possible outcomes. [Level 5]</p>
        <p>There is conflicting evidence on the effect of inhaled corticosteroids on bone metabolism and osteoporosis. High doses of ICS correlate with an increased risk of fracture. Adult patients on chronic ICS therapy should have periodic bone density measurements. Routine testing of bone density in children is not needed, but the recommendation is for supplementation with adequate vitamin D and calcium.<xref ref-type="bibr" rid="article-20046.r12">[12]</xref></p>
      </sec>
      <sec id="article-20046.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20046&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20046">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20046/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20046">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20046.s9">
        <title>References</title>
        <ref id="article-20046.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <collab>National Asthma Education and Prevention Program</collab>
            <article-title>Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>120</volume>
            <issue>5 Suppl</issue>
            <fpage>S94</fpage>
            <page-range>S94-138</page-range>
            <pub-id pub-id-type="pmid">17983880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnes</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Inhaled Corticosteroids.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2010</year>
            <month>Mar</month>
            <day>08</day>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>514</fpage>
            <page-range>514-540</page-range>
            <pub-id pub-id-type="pmid">27713266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bateman</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Hurd</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Bousquet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Drazen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>FitzGerald</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ohta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>O'Byrne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Pizzichini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Wenzel</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Zar</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Global strategy for asthma management and prevention: GINA executive summary.</article-title>
            <source>Eur Respir J</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>143</fpage>
            <page-range>143-78</page-range>
            <pub-id pub-id-type="pmid">18166595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reddel</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>FitzGerald</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bateman</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Bacharier</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brusselle</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Buhl</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yorgancioglu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boulet</surname>
                <given-names>LP</given-names>
              </name>
            </person-group>
            <article-title>GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents.</article-title>
            <source>Eur Respir J</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>53</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">31249014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tashkin</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Strange</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?</article-title>
            <source>Int J Chron Obstruct Pulmon Dis</source>
            <year>2018</year>
            <volume>13</volume>
            <fpage>2587</fpage>
            <page-range>2587-2601</page-range>
            <pub-id pub-id-type="pmid">30214177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rabe</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Hurd</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anzueto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Buist</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Calverley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fukuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rodriguez-Roisin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van Weel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zielinski</surname>
                <given-names>J</given-names>
              </name>
              <collab>Global Initiative for Chronic Obstructive Lung Disease</collab>
            </person-group>
            <article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2007</year>
            <month>Sep</month>
            <day>15</day>
            <volume>176</volume>
            <issue>6</issue>
            <fpage>532</fpage>
            <page-range>532-55</page-range>
            <pub-id pub-id-type="pmid">17507545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Bielory</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Derendorf</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dluhy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Colice</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Szefler</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Inhaled corticosteroids: past lessons and future issues.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>112</volume>
            <issue>3 Suppl</issue>
            <fpage>S1</fpage>
            <page-range>S1-40</page-range>
            <pub-id pub-id-type="pmid">14515117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geller</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler.</article-title>
            <source>Respir Care</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>50</volume>
            <issue>10</issue>
            <fpage>1313</fpage>
            <page-range>1313-21; discussion 1321-2</page-range>
            <pub-id pub-id-type="pmid">16185367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Geffen</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Douma</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Slebos</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kerstjens</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Aug</month>
            <day>29</day>
            <volume>2016</volume>
            <issue>8</issue>
            <fpage>CD011826</fpage>
            <pub-id pub-id-type="pmid">27569680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Capanoglu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dibek Misirlioglu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Toyran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Civelek</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kocabas</surname>
                <given-names>CN</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of inhaler technique, adherence to therapy and their effect on disease control among children with asthma using metered dose or dry powder inhalers.</article-title>
            <source>J Asthma</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>52</volume>
            <issue>8</issue>
            <fpage>838</fpage>
            <page-range>838-45</page-range>
            <pub-id pub-id-type="pmid">26037396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baptist</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Inhaled corticosteroids for asthma: are they all the same?</article-title>
            <source>J Clin Pharm Ther</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">19125898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanania</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Kesten</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of inhaled corticosteroids.</article-title>
            <source>Am J Med</source>
            <year>1995</year>
            <month>Feb</month>
            <volume>98</volume>
            <issue>2</issue>
            <fpage>196</fpage>
            <page-range>196-208</page-range>
            <pub-id pub-id-type="pmid">7847437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lavy</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Harries</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Dysphonia associated with inhaled steroids.</article-title>
            <source>J Voice</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>581</fpage>
            <page-range>581-8</page-range>
            <pub-id pub-id-type="pmid">11130115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fukushima</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Matsuse</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tomari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Obase</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyazaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shimoda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kohno</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>90</volume>
            <issue>6</issue>
            <fpage>646</fpage>
            <page-range>646-51</page-range>
            <pub-id pub-id-type="pmid">12839324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simon</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Houser</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Esophageal candidiasis as a complication of inhaled corticosteroids.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>1997</year>
            <month>Oct</month>
            <volume>79</volume>
            <issue>4</issue>
            <fpage>333</fpage>
            <page-range>333-8</page-range>
            <pub-id pub-id-type="pmid">9357379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia-Cuesta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sarrion-P&#x000e9;rez</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Bag&#x000e1;n</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Current treatment of oral candidiasis: A literature review.</article-title>
            <source>J Clin Exp Dent</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>e576</fpage>
            <page-range>e576-82</page-range>
            <pub-id pub-id-type="pmid">25674329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heffler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Madeira</surname>
                <given-names>LNG</given-names>
              </name>
              <name>
                <surname>Ferrando</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Puggioni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Racca</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Malvezzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Passalacqua</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Canonica</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2018</year>
            <season>May-Jun</season>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>776</fpage>
            <page-range>776-781</page-range>
            <pub-id pub-id-type="pmid">29408385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nowak-Wegrzyn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Beyer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bardina</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sampson</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Contamination of dry powder inhalers for asthma with milk proteins containing lactose.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>113</volume>
            <issue>3</issue>
            <fpage>558</fpage>
            <page-range>558-60</page-range>
            <pub-id pub-id-type="pmid">15007361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robijn</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>VE</given-names>
              </name>
            </person-group>
            <article-title>Inhaled corticosteroid use during pregnancy among women with asthma: A systematic review and meta-analysis.</article-title>
            <source>Clin Exp Allergy</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>49</volume>
            <issue>11</issue>
            <fpage>1403</fpage>
            <page-range>1403-1417</page-range>
            <pub-id pub-id-type="pmid">31357230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20046.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smy</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Bozzo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Is it safe to use inhaled corticosteroids in pregnancy?</article-title>
            <source>Can Fam Physician</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>60</volume>
            <issue>9</issue>
            <fpage>809</fpage>
            <page-range>809-12, e433-5</page-range>
            <pub-id pub-id-type="pmid">25217675</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
